What Money Can’t Build

The best founders don’t raise capital to start moving. They raise it when moving faster becomes more valuable than staying capital-efficient.

There is a version of the venture capital origin story in which capital is the enabling condition. Without the wire transfer, nothing begins. The team cannot be assembled, the equipment cannot be purchased, the experiments cannot be run. Capital is the substrate on which everything else is built.

I have been building a medtech venture in the UAE for two years without institutional capital. Not slowly. Literally without it.

During that period, we still managed to assemble a multidisciplinary team, put strong research infrastructure in place, conducted early studies, filed a provisional patent and moved a first device towards prototyping. We have attracted senior medical and scientific profiles, built hardware and data science capabilities, completed first-wave user research and started discussions around clinical research partnerships in the UAE and the UK.

None of this is an argument against venture capital, nor am I suggesting that money is not needed. Quite the opposite. Building without it has forced me to develop a more precise understanding of what venture capital actually contributes, and what founders who lack it must learn to supply in its place.

It has also made me question a distinction that is too rarely made in early-stage investing: the difference between capital that enables something to begin and capital that accelerates something already in motion.

When money isn’t available, something else has to be

When it comes to early-stage team building, the transaction appears fairly straightforward: offer equity to compensate for below-market cash or, in some cases, no cash at all. That is correct as far as it goes. But it understates the role of the underlying mission in determining whether equity is sufficient compensation for a particular person at a particular moment.

The people who joined Yuthera without compensation are not primarily motivated by equity. Every one of us is motivated by a condition that medicine has largely ignored for decades: chronic pelvic pain, affecting hundreds of millions of women, for which the current standard of care can range from inadequate to actively harmful. Several members of the team have experienced the condition themselves. Most of us have watched people we care about manage it and suffer silently. The equity is real, and it matters. But it is not the primary mechanism. At least not for us.

This is obviously not a scalable hiring strategy for every company or every category. I would be dishonest if I suggested that every conversation has produced talent aligned with that motivation. Mission cannot permanently substitute for salaries, and conviction does not pay people’s bills. But for companies working on problems where the human stakes are visible and the need for better solutions is personally felt by those qualified to contribute, mission can temporarily function as a form of capital. That matters for investors evaluating pre-revenue teams. A founder’s ability to assemble talented people before being able to pay market salaries does not validate the product or the market. But it does reveal something about persuasion, leadership and the capacity to mobilise resources that do not yet sit on the balance sheet.

The same applies to infrastructure. The conventional framing of university-startup collaboration positions the university as a source of IP and the startup as the go-to-market vehicle. The university generates science; the startup takes it to market. The relationship is largely transactional. What this framing misses is a more interesting dynamic, particularly in emerging innovation ecosystems. In the UAE, universities are also attempting to demonstrate that they are commercially and institutionally relevant in a region actively building its own knowledge economy. This can create a window in which a founder with a credible problem, a coherent plan and the willingness to show up can access research resources, engineering expertise, regulatory knowledge and institutional credibility that would be extremely expensive to replicate commercially.

I discovered this in a fairly literal way. I drove to the University of Sharjah and Khalifa University without appointments. I arrived, explained what we were building and asked for research partnerships. At the University of Sharjah, I sat outside the research institute director’s office for hours before getting the opportunity to make the case. Those conversations ultimately opened access to fabrication and testing infrastructure, biomedical engineering expertise, data architecture capabilities and government-linked prototyping resources. The infrastructure was already there. What was missing was a sufficiently credible reason to deploy it.

That distinction matters. Resource-constrained founders are constantly doing some version of this: identifying resources they cannot afford to purchase and finding another mechanism through which they can be mobilised. Sometimes that mechanism is equity. Sometimes it is mission. Sometimes it is institutional alignment, reputation, partnership or simple persistence.

Money is one mechanism for allocating resources. It is not always the only one.

The best capital accelerates what already works

Building without capital does not diminish the contribution capital makes at the right stage. If anything, it clarifies it. Where venture capital becomes most valuable is not necessarily as an enabling condition, but as an acceleration mechanism. The question is not simply whether a startup can exist without institutional funding. Some can, and for considerably longer than investors might assume. The more useful question is whether the company can reach its next threshold of technical, commercial or institutional credibility within the time available.

For a medical-device company such as Yuthera, that threshold might be a working prototype followed by the evidence required to move towards clinical validation. For a SaaS company, it might be the first hundred enterprise customers. Capital accelerates the journey towards those thresholds. But it does not necessarily determine whether the threshold is reachable. This creates an important distinction for both founders and investors. Founders who understand precisely what capital will accelerate tend to make a more compelling fundraising argument. They can explain what already exists, what the new capital unlocks, what milestones it should produce and why reaching those milestones faster is worth the dilution.

The alternative is a fundraising proposition in which almost everything begins after the cheque arrives: once funded, we will hire the team; once funded, we will build the prototype; once funded, we will discover whether the organisation can actually execute. From an investor’s perspective, that is a materially different risk. This does not mean every founder should bootstrap a deep-tech company for years. In many categories, that would be impossible. But early resourcefulness provides investors with information. It says something about what might be called a founder’s conversion efficiency: the amount of organisational and technical progress that can be produced from a limited pool of financial resources. That is particularly relevant in deep tech, where the capital requirements eventually become substantial. The most valuable venture capital is therefore not necessarily the largest cheque or even the earliest one. It is capital arriving when the founder has demonstrated enough resourcefulness to show that the money will accelerate something real rather than merely initiate something uncertain. That should change both how founders raise and how investors underwrite them.

Eventually, resourcefulness meets startup physics

There is, however, a danger in romanticising all of this. Resourcefulness is a great asset, but it is not an infinite substitute for capital. Founders who confuse resilience with strategy will eventually discover the difference, often at considerable cost.

Clinical trials require capital. Not because the science is unavailable or patients are unwilling, but because regulatory processes require documentation, oversight, quality systems and institutional infrastructure with genuine costs. Regulatory submissions require capital. International expansion requires capital. Manufacturing at the scale necessary to convert a working prototype into a commercially viable product almost always requires capital. And mission-driven hires still have mortgages, families and living expenses. Mission does not pay those bills indefinitely. There is therefore a point at which capital scarcity stops creating discipline and starts creating delay.

A founder who finds a creative way to avoid spending $100,000 while achieving essentially the same result may have demonstrated excellent capital efficiency. A founder who spends six additional months avoiding an expenditure that could have compressed the same milestone into six weeks may simply be running an undercapitalised company. That distinction is critical.

Capital scarcity is useful when it forces prioritisation. It becomes destructive when it forces delay.

The appropriate conclusion is therefore not that capital is unnecessary. It is that a founder’s demonstrated ability to build without it changes the terms on which capital should be sought, and, potentially, the terms on which it should be offered. A company that has assembled a credible team, established research partnerships, attracted clinical advisers and moved towards a working prototype without institutional funding is not asking an investor for its first injection of belief. It is asking for an accelerant for a fire that is already burning.

That is a materially different ask. For founders, it changes the fundraising conversation from “here is what we will begin once you fund us” to “here is what we have already demonstrated, here is the constraint we have now reached, and here is precisely what your capital allows us to accelerate.”

For investors, the question should change too. Not simply: What will you build if we fund you? But: What have you already learned how to build without us, and what becomes possible once time, rather than money, becomes the scarce resource?